Please enable Javascript
SUO Annual Meeting 2021
In-depth coverage of the SUO Annual Meeting 2021
Trends of Active Surveillance Management in Men With Low- and Intermediate-Risk Prostate Cancer
GU Oncology Now Editors
SUO Annual Meeting 2021
|
December 3, 2021
Active surveillance, standard of care for low-risk prostate cancer, may be safe for patients with intermediate-risk disease.
Prostate-Specific Antigen Screening Intensities and Racial Disparity in Prostate Cancer Diagnoses
GU Oncology Now Editors
SUO Annual Meeting 2021
|
September 19, 2022
Researchers evaluate PSA screening frequency and the effect of different screening intensities on prostate cancer diagnoses.
CxBladder Monitor Testing to Inform the Need for Surveillance Cystoscopy
GU Oncology Now Editors
SUO Annual Meeting 2021
|
February 5, 2024
The CxBladder Monitor urine test is feasible and safe for patients on surveillance for NMIBC.
Medical Spending Across Specialties: Urology's Contribution to Financial Toxicity
GU Oncology Now Editors
SUO Annual Meeting 2021
|
March 6, 2023
Urologists contribute the most to Medicare Part D medication costs, likely because of high-cost urologic cancer care meds.
Natural Language Processing Algorithm Evaluates Trials’ Kidney Function Inclusion Criteria
GU Oncology Now Editors
SUO Annual Meeting 2021
|
December 2, 2021
Researchers used a natural language processing method to analyze kidney function inclusion criteria for a clinical trial.
Do Academic Centers Affect Racial and Insurance-Based Survival Disparities in Muscle-Invasive Bladder Cancer?
GU Oncology Now Editors
SUO Annual Meeting 2021
|
September 19, 2022
Researchers observed treatment for MIBC in academic facilities didn’t mitigate poorer outcomes for disadvantaged ...
Novel AUA Risk Groups for Localized Renal Cancer Validated by Mayo Clinic Risk Model
GU Oncology Now Editors
SUO Annual Meeting 2021
|
December 2, 2021
Researchers evaluated the new AUA risk stratification system for survival in patients with clear cell or papillary RCC.
Treatment With 177Lu-PSMA-I&T Prior to Radical Prostatectomy in High-Risk Prostate Cancer
GU Oncology Now Editors
SUO Annual Meeting 2021
|
November 30, 2022
177Lu-PSMA-I&T followed by radical prostatectomy with PLND appeared safe in patients with high-risk prostate cancer.
Inferior Outcomes at Hospitals Serving Disparity Populations for Patients With Prostate Cancer
GU Oncology Now Editors
SUO Annual Meeting 2021
|
September 19, 2022
For prostate cancer patients, variables like definitive treatment and time to treatment initiation are inferior at HSDPs.
Survival Predictors in Patients with Renal Cell Carcinoma and Inferior Vena Cava Tumor Thrombus
GU Oncology Now Editors
SUO Annual Meeting 2021
|
December 1, 2021
Researchers identified survival predictors in patients with renal cell carcinoma with inferior vena cava thrombus.
Cost Comparison of Different Transperineal Prostate Biopsy Methods
GU Oncology Now Editors
SUO Annual Meeting 2021
|
December 1, 2021
Cost analysis was used to evaluate whether transperineal prostate biopsy is superior to standard transrectal prostate biopsy.
Renal Function Preservation of Active Surveillance Versus Partial Nephrectomy in Oncocytoma
GU Oncology Now Editors
SUO Annual Meeting 2021
|
December 1, 2021
Active surveillance doesn’t result in inferior renal function compared with partial nephrectomy in patients with ...
Advertisement
Advertisement
Advertisement
Advertisement